GlassScriptPhysician profile
Mohammad Mashayekh
NPI 1700224656
$952.72
in general payments reported to CMS, 2019-2025
14 companies · $144 in 2025
The $144 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.96 · 2020: $39.62 · 2021: $92.29 · 2022: $93.12 · 2023: $164 · 2024: $335 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $232.99 | 2019-2025 | Sublocade, Perseris |
| Alkermes, INC. | $219.80 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $142.47 | 2021-2024 | |
| Orexo US, INC. | $85.96 | 2022-2025 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $66.74 | 2024-2025 | Cobenfy |
| Uswm, LLC | $51.55 | 2024 | Lucemyra |
| Janssen Pharmaceuticals, INC | $25.89 | 2024 | Invega Sustenna |
| Neos Therapeutics, LP | $24.91 | 2024 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $24.57 | 2024 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.19 | 2019 | |
| Braeburn INC. | $17.81 | 2024 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $16.15 | 2019 | |
| Bioxcel Therapeutics, INC. | $13.23 | 2023 | Igalmi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Mashayekh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.